ReviewFrontiers in bioengineering and biotechnology2025
Organoids in cancer therapies: a comprehensive review.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Hydrogels Activated with Plant Extracts/Bioactive Compounds for Cancer Treatment: From Design to Application.Gels (Basel, Switzerland) · 2026Review
- Organoid technology in cancer research.Molecular biomedicine · 2026Review
- Emerging role of microRNAs as modulators of the tumor immune microenvironment.Journal for immunotherapy of cancer · 2026Review
- Modelling brain tumours with organoids: towards precision medicine in neuro-oncology.Nature reviews. Neurology · 2026Review
- C-X-C chemokine receptor type 4 (CXCR4) antagonism in precision oncology: Clinical applications and future directions.Cancer pathogenesis and therapy · 2026Review
- Engineering the Human Endometrial-Embryo Interface: Breakthroughs in 3D Uterine Models.Biomolecules · 2026Review
- Integrating New Approach Methodologies (NAMs) into Preclinical Regulatory Evaluation of Oncology Drugs.Biomimetics (Basel, Switzerland) · 2025Review
- Review
- Construction of bioactive nanocomposites from beta-sitosterol, fucoidan, chitosan, and silver nanoparticles for anticancer applications.Frontiers in bioengineering and biotechnology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organoid technology has significantly advanced biomedical research, offering deep insights into tumor biology and therapeutic efficacy. While existing publications have covered organoid applications, this review uniquely stresses their transformative role in cancer research. We highlight their importance in studying intratumoral heterogeneity and microenvironment interactions. Our analysis addresses knowledge gaps by detailing how organoids function as models in cancer initiation, drug screening, target identification, and sensitivity assessment. We also explore their applications in personalized medicine, such as developing patient-derived models for treatment prediction and immune therapy evaluation. This review discusses the latest progress in using organoids for cancer treatment, like predicting patient responses to precision medicine. However, challenges remain, including maintaining genetic stability and mimicking
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.